Aortic valve replacement in patients with systemic mastocytosis

Journal of Cardiac Surgery

Volumn 27, Issue 2, 2012, Pages 189-191

  Wanamaker, Kelly M ^a   Magovern Jr , George J ^a   Moraca, Robert J ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLIMIDAZOLE; CARBAMAZEPINE; DIPHENHYDRAMINE; ETOMIDATE; FAMOTIDINE; FENTANYL; FEXOFENADINE; ISOFLURANE; LITHIUM; METHYLPREDNISOLONE; MORPHINE; N METHYLHISTAMINE; PARACETAMOL; RANITIDINE;

AGED; ANALGESIA; AORTA STENOSIS; AORTA VALVE REPLACEMENT; ARTICLE; CASE REPORT; DYSPNEA; FEMALE; HEART EJECTION FRACTION; HUMAN; PEROPERATIVE CARE; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRURITUS; SYSTEMIC MASTOCYTOSIS; THORAX PAIN; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME;

AGED; AORTIC VALVE STENOSIS; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MASTOCYTOSIS, SYSTEMIC; PERIOPERATIVE CARE;

EID: 84859444333     PISSN: 08860440     EISSN: 15408191     Source Type: Journal    
DOI: 10.1111/j.1540-8191.2011.01404.x     Document Type: Article

References (16)

1. Butterfield JH: Systemic mastocytosis: Clinical manifestations and differential diagnosis. Immunol Allergy Clin North Am 2006;26:487-513.
2. Paparella D, Yau TM, Young E: Cardiopulmonary bypass induced inflammation: Pathophysiology and treatment: An update. Eur J Cardiothorac Surg 2002;21:232-244. (Pubitemid 34135370)
3. Keyzer JJ, de Monchy J, van Doormaal JJ, et al: Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. N Engl J Med 1983;309:1603-1605. (Pubitemid 14204236)
4. Damodar S, John CN, Shetty DP, et al: Mast cell disease: Surgical and anaesthetic implications. J Pediatr Hematol Oncol 2006;28:446.
5. Moro JA, Almenar L, Jarque I, et al: Heart transplantation in a patient with systemic mastocytosis. J Heart Lung Transplant 2008;27(6):689-691. (Pubitemid 351707624)
6. Akin C: Molecular diagnosis of mast cell disorders: A paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006;8:412-419.
7. Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114(5):937-951.
8. Alto WA, Clarcq L: Cutaneous and systemic manifestations of mastocytosis. Am Fam Physician 1999;59:3047-3054, 3059-3060.
9. Chaar CL, Bell RL, Duffy PT, et al: Guidelines for safe surgery in patients with systemic mastocytosis. Am Surg 2009;75(1):74-80. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19213401.
10. ParrisWC, Scott HW, Smith BE: Anesthetic management of systemic mastocytosis: Experience with 42 cases. Anesth Analg 1986;65:S1-S170.
11. Smith GB, Gusberg RJ, Jordan RH, et al: Histamine levels and cardiovascular responses during splenectomy and splenorenal shunt formation in a patient with systemic mastocytosis. Anaesthesia 1987;42:861-867. (Pubitemid 17103868)
12. Villeneuve V, Kaufman I, Weeks S, et al: Anesthetic management of a laboring parturient with urticarial pigmentosa. Can J Anaesthesiol 2006;53:380-384. (Pubitemid 43670548)
13. Borgeat A, Ruetsch YA: Anesthesia in a patient with malignant mastocytosis using a total intravenous anesthetic technique. Anesth Analg 1998;86:442-444. (Pubitemid 28079509)
14. Rosenbaum KJ, Strobel GE: Anesthetic considerations in mastocytosis. Anesthesiology 1973;38:398-401.
15. Rosow CE, Moss J, Philbin DM, et al: Histamine release duringmorphine and fentanyl anesthesia. Anesthesiology 1982;56(2):93-96. (Pubitemid 12164872)
16. Scott HW, Parris WCV, Sandidge PC, et al: Hazards in operative management of patients with systemic mastocytosis. Ann Surg 1983;197:507-514. (Pubitemid 13080039)